Search
Support us
Beijnen

Jos Beijnen

Anticancer drug development

Our group specialises in pharmacology and the development of anti cancer drugs.

 

More about this group

Our research

Clinical Trials with targeted therapies

Team members

Beijnen Profiel
Jos Beijnen Group leader
Pauline Buitelaar
Pauline Buitelaar PhD student
NKI Placeholder Profiel
Wan-Yu Chu PhD student
Maud Van Der Kleij
Maud van der Kleij PhD student
Anke Leeuwerik
Anke Leeuwerik PhD student
NKI Placeholder Profiel
Lishi Lin PhD student
NKI Placeholder Profiel
Marinda Meertens PhD student
NKI Placeholder Profiel
Dick Pluim Analist
NKI Placeholder Profiel
Irene Retmana PhD student
Hinke Siebinga
Hinke Siebinga PhD student
+ -9
Show more

News and stories

Highly Cited Researcher 2023
Five researchers from the Netherlands Cancer Institute recognized as highly cited researcher 2023
14-11-2023
Highly Cited Researchers 550X320
Five researchers from the Netherlands Cancer Institute recognized as highly cited researcher 2022
15-11-2022
Theses Defense Marie Rose Preview Photo 1
Thesis defense Marie-Rose Crombag anti-cancer drugs in the elderly
05-09-2019
More news

Publications of this group

Investigational new drugs

Extrahepatic metabolism of ibrutinib.

01-02-2021
Key Publication
Biomedical chromatography : BMC

Validated LC-MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI-0690 in Preclinical Target Site PK/PD Studies.

01-08-2025
More publications

More about our collaborations

Alfred Schinkel Group
Pharmacology Alfred Schinkel

Investigation of how the body deals with anticancer drugs.
Olaf Van Tellingen Group
Glioblastoma biology and treatment Olaf van Tellingen

Identify drugs that target the vulnerabilities of tumors.

Contact our group

NKI Placeholder Profiel
Sarah Stolk Office Manager
Phone Email

Learn more about our...

Facilities & Platforms Researchers

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.